Earnings Scheduled For March 9, 2023
Companies Reporting Before The Bell
• Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.
Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce
Aligos Therapeutics Inc (NASDAQ:ALGS) announced a portfolio reprioritization, with priorities focused on the rapid advancement of its clinical NASH (ALG-055009)…
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.
Piper Sandler Maintains Overweight on Aligos Therapeutics, Raises Price Target to $7
Piper Sandler analyst Yasmeen Rahimi maintains Aligos Therapeutics (NASDAQ:ALGS) with a Overweight and raises the price target from $3 to $7.
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Nymox Pharmaceutical (NASDAQ:NYMX) stock moved upwards by 20.7% to $0.52 during Monday’s after-market session. The market value…
Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…
Jefferies Upgrades Aligos Therapeutics to Buy, Raises Price Target to $3
Jefferies analyst Michael Yee upgrades Aligos Therapeutics (NASDAQ:ALGS) from Hold to Buy and raises the price target from $2.5 to $3.
Aligos Therapeutics Initiates Dosing With Its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, In Subjects With Chronic Hepatitis B
Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported today that dosing with
SVB Leerink Maintains Market Perform Rating for Aligos Therapeutics: Here’s What You Need To Know
SVB Leerink has decided to maintain its Market Perform rating of Aligos Therapeutics (NASDAQ:ALGS) and lower its price target from $3.00 to $2.00.
Shares of Aligos Therapeutics are trading up 0.0% over the last 24 hours, at $1.07 per share.